Suppression of Metastases Using a New Lymphocyte Checkpoint Target for Cancer Immunotherapy

Abstract

This article illustrates the antimetastatic activity and mechanism of action of an anti-CD96 antibody that inhibits the CD96-CD155 interaction and stimulates NK-cell function. Targeting host CD96 is shown to complement surgery and conventional immune checkpoint blockade.